Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob M Rowe

Showing results (171-180 of 275) with videos related to

Pageof 28
Sort By:
Blood|August 3, 2012
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900Mithat Gönen, Zhuoxin Sun, Maria E Figueroa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)Peter L Greenberg, Sandra J Lee, Ranjana Advani, et al.
Annals of Hematology|May 15, 2014
Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA studyMathias Witzens-Harig, Robin Foá, Alice Di Rocco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemiaAnthony V Moorman, Claire Schwab, Hannah M Ensor, et al.
Leukemia Research|July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patientsJustin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Blood|March 22, 2007
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remissionMartin S Tallman, Gordon W Dewald, Sharavi Gandham, et al.
Blood Advances|October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trialsChezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.
Blood|October 24, 2002
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolMartin S Tallman, Janet W Andersen, Charles A Schiffer, et al.
Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.
The Lancet. Haematology|February 2, 2019
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 studyNoelle Frey, Jun Ho Jang, Jeff Szer, et al.
Pageof 28

Showing results (171-180 of 275) with videos related to

Sort By:
Pageof 28
Blood|August 3, 2012
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900Mithat Gönen, Zhuoxin Sun, Maria E Figueroa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)Peter L Greenberg, Sandra J Lee, Ranjana Advani, et al.
Annals of Hematology|May 15, 2014
Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA studyMathias Witzens-Harig, Robin Foá, Alice Di Rocco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemiaAnthony V Moorman, Claire Schwab, Hannah M Ensor, et al.
Leukemia Research|July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patientsJustin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Blood|March 22, 2007
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remissionMartin S Tallman, Gordon W Dewald, Sharavi Gandham, et al.
Blood Advances|October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trialsChezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.
Blood|October 24, 2002
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolMartin S Tallman, Janet W Andersen, Charles A Schiffer, et al.
Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.
The Lancet. Haematology|February 2, 2019
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 studyNoelle Frey, Jun Ho Jang, Jeff Szer, et al.
Pageof 28